Financial Contrast: Biotricity (OTCMKTS:BTCY) and Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics (NASDAQ:FLGT) and Biotricity (OTCMKTS:BTCY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Profitability

This table compares Fulgent Genetics and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-13.62%	-2.55%	-2.36%
Biotricity	-30.02%	N/A	-75.50%

Valuation & Earnings

This table compares Fulgent Genetics and Biotricity”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$283.47 million	2.99	-$42.71 million	($1.39)	-19.76
Biotricity	$12.06 million	1.09	-$8.42 million	($0.17)	-2.76

Biotricity has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 33.1% of Fulgent Genetics shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Fulgent Genetics and Biotricity, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1	1	2	0	2.25
Biotricity	0	0	0	0	0.00

Fulgent Genetics presently has a consensus price target of $32.00, indicating a potential upside of 16.53%. Given Fulgent Genetics’ stronger consensus rating and higher possible upside, research analysts plainly believe Fulgent Genetics is more favorable than Biotricity.

Risk and Volatility

Fulgent Genetics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Summary

Fulgent Genetics beats Biotricity on 9 of the 14 factors compared between the two stocks.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.